The Use of Levosimendan in the Treatment of Neurogenic Stress Cardiomyopathy in a Patient with Nontraumatic Subarachnoid Hemorrhage (Case Report)

We present a case of cardiogenic shock due to neurogenic stress cardiomyopathy (NSC) in a patient with nontraumatic subarachnoid hemorrhage caused by a ruptured aneurysm of the right pericallosal artery. Due to the catecholamine-resistant shock, levosimendan was administered under advanced hemodynamic control, including transpulmonary thermodilution and echocardiography. This resulted in an improved cardiac contractility and reduced demand for catecholamines. Full stabilization of hemodynamic parameters was achieved by day 5. In the discussion section we reviewed available published case reports of using levosimendan in stress cardiomyopathy treatment.

1. Zaroff J.G., Rordorf G.A., Ogilvy C.S., Picard M.H. Regional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: evidence for neurally mediated cardiac injury. J Am Soc Echocardiogr. 2000; 13: 774–779. DOI: 10.1067/mje.2000.105763

2. Naidech A.M., Kreiter K.T., Janjua N., Ostapkovich N.D., Parra A., Commichau C., Fitzsimmons B-F.M., Connolly E.S., Mayer S.A. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation. 2005; 112: 2851–2856. DOI: 10.1067/mje.2000.105763

3. Bybee K.A., Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008; 118 (4): 397–409. DOI: 10.1161/circulationaha.106.677625

4. Elrifai A.M., Bailes J.E., Shih S.R., Dianzumba S., Brillman J. Characterization of the car- diac effects of acute subarachnoid hemorrhage in dogs. Stroke. 1996; 27: 737–741. DOI: 10.1161/01.str.27.4.737

5. Lyon A.R., Rees P.S., Prasad S., Poole-Wilson P.A., Harding S.E. Stress (takotsubo) cardiomyopathy a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med. 2008; 5: 22–29. DOI: 10.1038/ncpcardio1066

6. Baroldi G., Mittleman R.E., Parolini M., Silver M.D., Fineschi V. Myocardial contraction bands. Definition, quantification and significance in forensic pathology. Int J Legal Med. 2001; 115: 142–151. PMID: 11775016 DOI: 10.1007/s004140100229

7. Grad A., Kiauta T., Osredkar J. Effect of elevated plasma norepinephrine on electro- cardiographic changes in subarachnoid hemorrhage. Stroke. 1991; 22: 746–749. DOI: 10.1161/01.str.22.6.746

8. Busani S., Rinaldi L., Severino C., Cobelli M., Pasetto A., Girardis M. Levosimendan in cardiac failure after subarachnoid hemorrhage. J Trauma. 2010; 68: E108–10. DOI: 10.1097/ta.0b013e31817c4284

9. Papanikolaou J., Tsolaki V., Makris D., Zakynthinos E. Early levosimendan administration may improve outcome in patients with subarachnoid hemorrhage complicated by acute heart failure. Int J Cardiol. 2014; 176 (3): 1435–1437. DOI: 10.1016/j.ijcard.2014.08.039

10. Taccone F.S., Brasseur A., Vincent J.L., De Backer D. Levosimendan for the treatment of subarachnoid hemorrhage-related cardiogenic shock. Inensive Care Med. 2013; 39 (8): 1497–1498. DOI: 10.1007/s00134-013-2945-5

11. Papp Z., Agostoni P., Alvarez J., Bettex D., Bouchez S., Brito D., Černý V., Comin-Colet J., Crespo-Leiro M.G., Delgado J.F., Édes I., Eremenko A.A., Farmakis D., Fedele F., Fonseca C., Fruhwald S., Girardis M., Guarracino F., Harjola V.-P., Heringlake M., Herpain A., Heunks L.M.A., Husebye T., Ivancan V., Karason K., Kaul S., Kivikko M., Kubica J., Masip J., Matskeplishvili S., Mebazaa A., Nieminen M.S., Oliva F., Papp J.G., Parissis J., Parkhomenko A., Põder P., Pölzl G., Reinecke A., Ricksten S.-E., Riha H., Rudiger A., Sarapohja T., Schwinger R.H.G., Toller W., Tritapepe L., Tschöpe C., Wikström G., von Lewinski D., Vrtovec B., Pollesello P. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Cardiovasc Pharmacol. 2020; 76 (1): 4–22. DOI: 10.1097/FJC.0000000000000859